Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study.

被引：0
|
作者：
Cartron, Guillaume
Bachy, Emmanuel
Tilly, Herve
Daguindau, Nicolas
Pica, Gian Matteo
Bijou, Fontanet
Mounier, Christiane
Clavert, Aline
Damaj, Gandhi Laurent
Slama, Borhane
Casasnovas, Olivier
Houot, Roch
Bouabdallah, Krimo
Sibon, David
Fitoussi, Olivier
Morineau, Nadine
Morschhauser, Franck
Xerri, Luc
Tarte, Karin
Pranger, Delphine
机构：
[1] CHU Montpellier, Montpellier, France
[2] Ctr Hospitalier Lyon Sud, Lyon, France
[3] Ctr Henri Becquerel, Rouen, France
[4] CH Annecy Genevois, Annecy, France
[5] CH Chambery, Chambery, France
[6] Inst Bergoni, Bordeaux, France
[7] Inst Cancerol Lucien Neuwirth, St Priest En Jarez, France
[8] CHU Angers, Angers, France
[9] CHU Amiens, Amiens, France
[10] CH Avignon, Avignon, France
[11] CHU Dijon, Dijon, France
[12] Hop Pontchaillou CHU Rennes, Rennes, France
[13] CHU Bordeaux, Bordeaux, France
[14] Hop Necker Enfants Malad, Paris, France
[15] Polyclin Bordeaux Nord, Bordeaux, France
[16] CH Roche Yon, La Roche Sur Yon, France
[17] CHU Lille, Lille, France
[18] Inst Paoli Calmettes, Marseille, France
[19] CHU Rennes, Rennes, France
[20] CH Charleroi, Charleroi, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7512
引用
收藏
页数：1
相关论文
共 32 条
  • [21] Favorable Impact of Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 on Overall Survival and Progression-Free Survival in Advanced Stage or Relapsed/Refractory Follicular Lymphoma: Results of a Phase II Study
    Eveillard, Jean-Richard
    Ianotto, Jean-Christophe
    Tempescul, Adrian
    Guillerm, Gaelle
    Dalbies, Florence
    Saad, Hussam
    Calloc'h, Ronan L. E.
    Dagorn, Anaig
    Sack, Francoise N'go
    Berthou, Christian
    BLOOD, 2011, 118 (21) : 1322 - 1322
  • [22] Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany)
    Rummel, Mathias J.
    Niederle, Norbert
    Maschmeyer, Georg
    Banat, Andre
    von Gruenhagen, Ulrich
    Losem, Christoph
    Heil, Gerhard
    Welslau, Manfred
    Balser, Christina
    Kaiser, Ulrich
    Ballo, Harald
    Weidmann, Eckhart
    Duerk, Heinz A.
    Kofahl-Krause, Dorothea
    Roller, Fritz
    Barth, Juergen
    Hoelzer, Dieter
    Hinke, Axel
    Brugger, Wolfram
    BLOOD, 2009, 114 (22) : 168 - 169
  • [23] Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study
    Townsend, William
    Buske, Christian
    Cartron, Guillaume
    Cunningham, David
    Dyer, Martin J. S.
    Gribben, John G.
    Hess, Georg
    Ishikawa, Takayuki
    Keller, Ulrich
    Kneba, Michael
    Malladi, Ram
    Neidhart, Jeffrey D.
    Rusconi, Chiara
    Zhu, Jun
    Catalani, Olivier
    Knapp, Andrea
    Zeuner, Harald
    Herold, Michael
    Hiddemann, Wolfgang
    Marcus, Robert
    BLOOD, 2018, 132
  • [24] Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study
    Le Gouill, Steven
    Thieblemont, Catherine
    Oberic, Lucie
    Bouabdallah, Krimo
    Gyan, Emmanuel
    Damaj, Gandhi
    Ribrag, Vincent
    Bologna, Serge
    Gressin, Remy
    Casasnovas, Olivier
    Haioun, Corinne
    Solal-Celigny, Philippe
    Maisonneuve, Herve
    Van Den Neste, Eric
    Moreau, Anne
    Bene, Marie C.
    Salles, Gilles
    Tilly, Herve
    Lamy, Thierry
    Hermine, Olivier
    BLOOD, 2014, 124 (21)
  • [25] BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study
    van Oers, Marinus H. J.
    Tonnissen, Evelyn
    Van Glabbeke, Martine
    Giurgea, Livia
    Jansen, Joop H.
    Klasa, Richard
    Marcus, Robert E.
    Wolf, Max
    Kimby, Eva
    Vranovsky, Andrej
    Holte, Harald
    Hagenbeek, Anton
    van der Reijden, Bert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2246 - 2252
  • [26] Rituximab Maintenance Versus Wait and Watch After Four Courses of R-DHAP Followed By Autologous Stem Cell Transplantation in Previously Untreated Young Patients With Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a LYSA Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 17 - 18
  • [27] Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group
    Kimby, Eva
    Ostenstad, Bjorn
    Brown, Peter de Nully
    Holte, Harald, Jr.
    Hagberg, Hans
    Erlanson, Martin
    Linden, Ola
    Nordstrom, Marie
    Sundstrom, Christer
    BLOOD, 2012, 120 (21)
  • [28] MAINTENANCE TREATMENT WITH IMMUNOMODULATOR MGN1703 FOLLOWING INDUCTION WITH STANDARD 1ST LINE THERAPY PROLONGS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH METASTATIC COLORECTAL (MCRC): RESULTS OF THE PHASE II/III IMPACT TRIAL
    Arnold, D.
    Schmoll, H. J.
    Riera-Knorrenschild, J.
    Mayer, F.
    Kroening, H.
    Scheithauer, W.
    Nitsche, D.
    Tschaika, M.
    Schmidt, M.
    Wittig, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 178 - 178
  • [29] Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809
    Fisher, RI
    Dana, BW
    LeBlanc, M
    Kjeldsberg, C
    Forman, JD
    Unger, JM
    Balcerzak, SP
    Gaynor, ER
    Roy, V
    Miller, T
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) : 2010 - 2016
  • [30] Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (1ST): Results of a multi-institutional phase II randomized study.
    Gomez, Daniel Richard
    Blumenschein, George R.
    Lee, J. Jack
    Hernandez, Mike
    Camidge, D. Ross
    Doebele, Robert Charles
    Gaspar, Laurie E.
    Gibbons, Don Lynn
    Karam, Jose A.
    Kavanagh, Brian D.
    Komaki, Ritsuko
    Louie, Alexander V.
    Palma, David A.
    Tsao, Anne S.
    William, William Nassib
    Zhang, Jianjun
    Swisher, Stephen
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
1234